Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$261 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.1
Industry P/E
28.02
EV/EBITDA
-2.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.2
Face value
--
Shares outstanding
109,714,000
CFO
$-461.46 Mln
EBITDA
$-526.01 Mln
Net Profit
$-537.26 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Annexon Inc (ANNX)
| -53.1 | 14.0 | 0.2 | -51.7 | -15.0 | -- | -- |
|
BSE Sensex
| 4.9 | 0.4 | 6.7 | 6.3 | 16.2 | 18.3 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Annexon Inc (ANNX)
| 12.9 | -12.2 | -55.0 | -54.1 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Annexon Inc (ANNX)
|
2.4 | 261.1 | 0.0 | -167.4 | -- | -58.2 | -- | 1.1 |
| 17.6 | 4,328.3 | 459.4 | 206.8 | 25.6 | 68.3 | 21.6 | 11.3 | |
| 8.0 | 3,640.5 | 2,830.2 | -13.1 | 11.5 | -- | -- | 86.1 | |
| 102.9 | 4,957.6 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 93.2 | |
| 54.4 | 10,547.7 | 2,937.8 | 523.9 | 23.2 | 9.3 | 20.4 | 1.8 | |
| 43.5 | 7,923.7 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 75.5 | 7,569.5 | 685.5 | 132.9 | 15.6 | 20.1 | 62.1 | 11.1 | |
| 13.3 | 6,684.9 | 4,427.0 | 373.0 | -0.7 | 5.8 | 17.9 | 1.1 | |
| 84.6 | 4,123.2 | 1,137.8 | 214.6 | 29.2 | 12.3 | 19.4 | 2.2 | |
| 8.9 | 10,410.5 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.7 |
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3... clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California. Address: 1400 Sierra Point Parkway, Brisbane, CA, United States, 94005 Read more
CEO, President & Director
Mr. Douglas Love Esq., J.D.
CEO, President & Director
Mr. Douglas Love Esq., J.D.
Headquarters
Brisbane, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Annexon Inc (ANNX) stood at $ 337 Mln as on 31-Mar-25
The share price of Annexon Inc (ANNX) is $2.41 (NASDAQ) as of 24-Jun-2025 11:41 EDT. Annexon Inc (ANNX) has given a return of -14.96% in the last 3 years.
Annexon Inc (ANNX) has a market capitalisation of $ 261 Mln as on 23-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Annexon Inc (ANNX) is 1.07 times as on 23-Jun-2025, a 77% discount to its peers’ median range of 4.74 times.
Since, TTM earnings of Annexon Inc (ANNX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Annexon Inc (ANNX) and enter the required number of quantities and click on buy to purchase the shares of Annexon Inc (ANNX).
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California. Address: 1400 Sierra Point Parkway, Brisbane, CA, United States, 94005
The CEO & director of Mr. Douglas Love Esq., J.D.. is Annexon Inc (ANNX), and CFO & Sr. VP is Mr. Douglas Love Esq., J.D..
There is no promoter pledging in Annexon Inc (ANNX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,059
|
|
|
1,029
|
|
|
762
|
|
|
761
|
|
|
676
|
|
|
507
|
|
|
433
|
|
|
414
|
|
|
368
|
| Annexon Inc (ANNX) | Ratios |
|---|---|
|
Return on equity(%)
|
-58.18
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Annexon Inc (ANNX) was $0 Mln.
$0.03
(
